Shots:
- The US FDA has granted clearance to Cala kIQ Plus system, a wearable neurostimulation device, for the treatment of action hand tremor in essential tremor (ET) & Parkinson’s disease (PD)
- The Cala kIQ device provides temporary relief of hand tremors in adults with essential tremor & Parkinson’s disease, incl. postural & kinetic tremors, using transcutaneous afferent patterned stimulation (TAPS) therapy to improve daily function
- Clinical data on Cala kIQ Plus to be presented at AAN’26 show improved efficacy with optimized TAPS therapy modes, demonstrating increased responder rates & bilateral tremor improvement in essential tremor
Ref: PRnewswire | Image: Cala | Press Release
Related News: QIAGEN Launches QIAstat-Dx BCID GPF Plus AMR Panel for Bloodstream Infection Syndromic Testing
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
